Holen Sie sich die Stockscreener-App
317.55
0.14%
-0.45
Schlusskurs vom Vortag:
$318.00
Offen:
$318.37
24-Stunden-Volumen:
240.92K
Relative Volume:
0.70
Marktkapitalisierung:
$12.51B
Einnahmen:
$1.45B
Nettoeinkommen (Verlust:
$171.05M
KGV:
73.07
EPS:
4.3459
Netto-Cashflow:
$212.73M
1W Leistung:
-0.42%
1M Leistung:
-1.63%
6M Leistung:
-3.88%
1J Leistung:
+25.27%
1-Tages-Spanne:
$316.78
$318.37
1-Wochen-Bereich:
$316.78
$319.33
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
317.55 | 12.56B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra stock breaks below 50-day average - AD HOC NEWS
IART vs. PEN: Which Stock Is the Better Value Option? - Zacks Investment Research
Average basic shares outstanding of Penumbra, Inc. – HAN:0P8 - TradingView
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Technical Signals Behind (PEN) That Institutions Follow - Stock Traders Daily
Anaconda Biomed raises $56m for catheter portfolio’s advance - Yahoo Finance
Penumbra stock reports 14.9 percent revenue growth - AD HOC NEWS
ETFs Investing in Penumbra, Inc. Stocks - TradingView
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential - DirectorsTalk Interviews
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation - AD HOC NEWS
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high - AD HOC NEWS
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Mechanical Clot Engagement Option for CAVT Thrombectomy Now Available - dicardiology.com
Penumbra Inc. (PEN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Penumbra, Inc. (PEN) Stock Analysis: Navigating Growth With A 13.88% Potential Upside - DirectorsTalk Interviews
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - DirectorsTalk Interviews
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 FCF Yield %: 1.79 — 2457% Above Median - GuruFocus
BSP:P2NB34 Market Cap: R$2,172 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) 12-1 Month Momentum % : N/A% (As of Sep. 05, 2026) - GuruFocus
BSP:P2NB34 3-Year RORE %: 46.88 | Fairly Valued - GuruFocus
BSP:P2NB34 PE Ratio (TTM): 2.55 — 99% Below Median - GuruFocus
Penumbra (BSP:P2NB34) 3-1 Month Momentum % : N/A% (As of Sep. 04, 2026) - GuruFocus
BSP:P2NB34 Net-Net Working Capital: R$75.32 | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Other Income (Minority Interest) : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
Penumbra (BSP:P2NB34) Repurchase of Stock : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
BSP:P2NB34 Forward PE Ratio: 1.72 | Fairly Valued - GuruFocus
Penumbra Inc Stock Operating Data - GuruFocus
BSP:P2NB34 Pre-Tax Income: R$1,082 Mil | Fairly Valued - GuruFocus
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - DirectorsTalk Interviews
Penumbra Inc. (PEN) Peer Comparison – Compare with Others - Value Research
Penumbra Inc. (PEN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Penumbra Inc. (PEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Incuvate Files Patent Infringement Lawsuit Against Penumbra - The Manila Times
Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential And Market Position - DirectorsTalk Interviews
Penumbra (PEN) Financial Update: EPS Does Not Reach the Reported Estimate at the Close; Investor Response: Shares Finish 0.43% DownAnnual Report - careplusvn.com
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):